

(see identification of Rho antagonist section).

SEQUENCE of (known) Rho antagonist C3 used in the experiments

Nucleotide sequence including part of the plasmid GST sequence. The vector with the GST sequence is commercially available and thus the entire GST sequence including the start was not sequenced. It was desired to determine only the sequence 3' to the thrombin cleavage site which releases C3 from the GST sequence. The thrombin cleavage site is shown with an arrow and is located just to the left of the underlined nucleotide sequence below (i.e. the arrow shows the thrombin cleavage site). The underlined sequence shows additional coding sequence translated in our recombinant protein that is not reported in the literature.

Both strands were sequenced to verify that there were no errors in the sequence.

5' GTG GCG ACC CTT CCC AAA TCG GAT CTG GTT CCG CGT GGA TCC TCT AGA  
GTC GAC CTG CAG GCA TGC AAT GCT TAT TCC ATT AAT CAA AAG GCT TAT TCA AAT ACT TAC  
 CAG GAG TTT ACT AAT ATT GAT CAA GCA AAA GCT TGG GGT AAT GCT CAG TAT AAA AAG TAT  
 GGA CTA AGC AAA TCA GAA AAA GAA GCT ATA GTA TCA TAT ACT AAA AGC GCT AGT GAA ATA  
 AAT GGA AAG CTA AGA CAA AAT AAG GGA GTT ATC AAT GGA TTT CCT TCA AAT TTA ATA AAA  
 CAA GTT GAA CTT TTA GAT AAA TCT TTT AAT AAA ATG AAG ACC CCT GAA AAT ATT ATG TTA  
 TTT AGA GGC GAC GAC CCT GCT TAT TTA GGA ACA GAA TTT CAA AAC ACT CTT CTT AAT TCA  
 AAT GGT ACA ATT AAT AAA ACG GCT TTT GAA AAG GCT AAA GCT AAG TTT TTA AAT AAA GAT  
 AGA CTT GAA TAT GGA TAT ATT AGT ACT TCA TTA ATG AAT GTT TCT CAA TTT GCA GGA AGA  
 CCA ATT ATT ACA AAA TTT AAA GTA GCA AAA GGC TCA AAG GCA GGA TAT ATT GAC CCT ATT  
 AGT GCT TTT CAG GGA CAA CTT GAA ATG TTG CTT CCT AGA CAT AGT ACT TAT CAT ATA GAC  
 GAT ATG AGA TTG TCT TCT GAT GGT AAA CAA ATA ATA ATT ACA GCA ACA ATG ATG GGC ACA  
 GCT ATC AAT CCT AAA TAA 3'

Nucleotide sequence of recombinant C3 protein: the sequence given below represents the entire coding sequence for the Rho antagonist used in the experiments mentioned herein. It is similar to the sequence shown above but does not include the GST portion which when the protein is made is enzymatically removed with thrombin.

1 GGATCCTCTA GAGTCGACCT GCAGGCATGC AATGCTTATT CCATTAATCA  
 51 AAAGGCTTAT TCAAATACTT ACCAGGAGTT TACTAATATT GATCAAGCAA  
 101 AAGCTTG GGG TAATGCTCAG TATAAAAAGT ATGGACTAAG CAAATCAGAA  
 151 AAAGAAGCTA TAGTATCATA TACTAAAAGC GCTAGTGAAA TAAATGGAAA  
 201 GCTAAGACAA AATAAGGGAG TTATCAATGG ATTCCTTCA AATTTAATAA  
 251 AACAA GTTGA ACTTTTAGAT AAATCTTTTA ATAAAATGAA GACCCCTGAA  
 301 AATATTATGT TATTTAGAGG CGACGACCTT GCTTATTTAG GAACAGAATT

351 TCAAAACACT CTCTTAATT CAAATGGTAC AATTAATAAA ACGGCTTTTG  
 401 AAAAGGCTAA AGCTAAGTTT TAAATAAAG ATAGACTTGA ATATGGATAT  
 451 ATTAGTACTT CATTAATGAA TGTTCCTCAA TTTGCAGGAA GACCAATTAT  
 501 TACAAAATTT AAAGTAGCAA AAGGCTCAAA GGCAGGATAT ATTGACCCTA  
 551 TTAGTGCTTT TCAGGGACAA CTTGAAATGT TGCTTCCTAG ACATAGTACT  
 601 TATCATATAG ACGATATGAG ATTGTCTTCT GATGGTAAAC AAATAATAAT  
 651 TACAGCAACA ATGATGGGCA CAGCTATCAA TCCTAAATAA

Amino acid sequence (one letter code)

Translation of the above sequence to show amino acid sequence. Amino acids in bold, highlight differences from published sequence (Popoff et al. (1990) Nucl. Acid. Res. 18:1291. EMBL accession no. X511464.) The 11 N-terminal sequences are additional; there is a single amino acid change of an alanine (hydrophobic) to glutamic acid (Q).

**GSSRVDLQAC** NAYSINQKAY SNTYQEFTNI DQAKAWGNAQ YKKYGLSKSE  
 KEAIVSYTKS ASEINGKLRQ NKGVINGFPS NLIKQVELLD KSFNKMKTPE NIMLFXGDDP  
 AYLGTETQNT LLNSNGTINK TAFEKAKAKF LNXDRLEYGY ISTSLMNVSQ FAGRPITKF  
 KVAKGSKAGY IDPISAFQGG LEMILLPRIIST YHIDDMRLSS DGKQIITAT MMGTAINPK

Number of amino acids: 229

Molecular weight: 25507.5

Theoretical pI: 9.43

Amino acid composition:

Ala (A)	18	7.9%
Arg (R)	6	2.6%
Asn (N)	18	7.9%
Asp (D)	10	4.4%
Cys (C)	1	0.4%
Gln (Q)	12	5.2%
Glu (E)	10	4.4%
Gly (G)	16	7.0%
His (H)	2	0.9%
Ile (I)	18	7.9%

Leu (L) 17 7.4%  
Lys (K) 23 10.0%  
Met (M) 7 3.1%  
Phe (F) 10 4.4%  
Pro (P) 7 3.1%  
Ser (S) 20 8.7%  
Thr (T) 14 6.1%  
Trp (W) 1 0.4%  
Tyr (Y) 11 4.8%  
Val (V) 6 2.6%

Asx (B) 0 0.0%  
Glx (Z) 0 0.0%  
Xaa (X) 2 0.9%

Total number of negatively charged residues (Asp + Glu): 20

Total number of positively charged residues (Arg + Lys): 29

Estimated half-life:

The N-terminal of the sequence considered is G (Gly).

The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).

>20 hours (yeast, in vivo).

>10 hours (Escherichia coli, in vivo).

Instability index:

The instability index (II) is computed to be 26.88

This classifies the protein as stable.

Aliphatic index: 75.07

Grand average of hydropathicity (GRAVY): -0.479 ]

Please also delete the following passage found on pages 46 to 51;

I SEQUENCE LISTING

(I) GENERAL INFORMATION:

(i) APPLICANT: LISA MCKERRACHER

(ii) TITLE OF INVENTION: Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: BROUILLETTE KOSIE

(B) STREET: 1100 RENE-LESVEQUE BLVD WEST

(C) PROV/STATE: QUEBEC

(D) COUNTRY: CANADA

(E) POSTAL/ZIP CODE: H3B 5C9

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: ASCII (TEXT)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: RONALD S. KOSIE

(B) REGISTRATION NO.: 28.814

(C) REFERENCE/DOCKET NO.: 06447-003-US-2

(D) TEL. NO.: (514) 397 8500

(E) FAX NO.: (514) 397 8515

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

## (ii) MOLECULE TYPE:

## (v) FRAGMENT TYPE:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM:

## (vii) IMMEDIATE SOURCE:

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(D) OTHER INFORMATION:

## (x) PUBLICATION INFORMATION:

(A) AUTHORS:

(B) TITLE:

(C) JOURNAL:

(D) VOLUME:

(E) ISSUE:

(F) PAGES:

(G) DATE:

(H) DOCUMENT NO.:

(I) FILING DATE:

(J) PUBLICATION DATE:

(K) RELEVANT RESIDUES IN SEQ ID NO:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTG GCG ACC CTT CCC AAA TCG GAT CTG GTT CCG CGT GGA TCC TCT AGA

```

      5              10              15
GTC GAC CTG CAG GCA TGC AAT GCT TAT TCC ATT AAT CAA AAG GCT TAT
      20              25              30
TCA AAT ACT TAC CAG GAG TTT ACT AAT ATT GAT CAA GCA AAA GCT TGG
      35              40              45
GGT AAT GCT CAG TAT AAA AAG TAT GGA CTA AGC AAA TCA GAA AAA GAA
      50              55              60
GCT ATA GTA TCA TAT ACT AAA AGC GCT AGT GAA ATA AAT GGA AAG CTA
      65              70              75              80
AGA CAA AAT AAG GGA GTT ATC AAT GGA TTT CCT TCA AAT TTA ATA AAA
      85              90              95
CAA GTT GAA CTT TTA GAT AAA TCT TTT AAT AAA ATG AAG ACC CCT GAA
      100             105             110
AAT ATT ATG TTA TTT AGA GGC GAC GAC CCT GCT TAT TTA GGA ACA GAA
      115             120             125
TTT CAA AAC ACT CTT CTT AAT TCA AAT GGT ACA ATT AAT AAA ACG GCT
      130             135             140
TTT GAA AAG GCT AAA GCT AAG TTT TTA AAT AAA GAT AGA CTT GAA TAT
      145             150             155             160
GGA TAT ATT AGT ACT TCA TTA ATG AAT GTT TCT CAA TTT GCA GGA AGA
      165             170             175
CCA ATT ATT ACA AAA TTT AAA GTA GCA AAA GGC TCA AAG GCA GGA TAT
      180             185             190
ATT GAC CCT ATT AGT GCT TTT CAG GGA CAA CTT GAA ATG TTG CTT CCT
      195             200             205
AGA CAT AGT ACT TAT CAT ATA GAC GAT ATG AGA TTG TCT TCT GAT GGT
      210             215             220
AAA CAA ATA ATA ATT ACA GCA ACA ATG ATG GGC ACA GCT ATC AAT CCT
      225             230             235             240
AAA TAA

```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGATCCTCTA GAGTCGACCT GCAGGCATGC AATGCTTATT CCATTAATCA 50  
AAAGGCTTAT TCAAACTACTT ACCAGGAGTT TACTAATATT GATCAAGCAA 100  
AAGCTTGGGG TAATGCTCAG TATAAAAAGT ATGGACTAAG CAAATCAGAA 150  
AAAGAAGCTA TAGTATCATA TACTAAAAGC GCTAGTGAAA TAAATGGAAA 200  
GCTAAGACAA AATAAGGGAG TTATCAATGG ATTCCTTCA AATTTAATAA 250  
AACAAGTTGA ACTTTTAGAT AAATCTTTTA ATAAAATGAA GACCCCTGAA 300  
AATATTATGT TATTTAGAGG CGACGACCCT GCTTATTTAG GAACAGAATT 350  
TCAAAACACT CTTCTTAATT CAAATGGTAC AATTAATAAA ACGGCTTTTG 400  
AAAAGGCTAA AGCTAAGTTT TTAAATAAAG ATAGACTTGA ATATGGATAT 450  
ATTAGTACTT CATTAATGAA TGTTTCTCAA TTTGCAGGAA GACCAATTAT 500  
TACAAAATTT AAAGTAGCAA AAGGCTCAAA GGCAGGATAT ATTGACCCTA 550  
TTAGTGCTTT TCAGGGACAA CTTGAAATGT TGCTTCCTAG ACATAGTACT 600  
TATCATATAG ACGATATGAG ATTGTCTTCT GATGGTAAAC AAATAATAAT 650  
TACAGCAACA ATGATGGGCA CAGCTATCAA TCCTAAATAA

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GSSRVIDLQAC NAYSINQKAY SNTYQEFNTI DQAKAWGNAQ YKKYGLSKSE 50  
KEAIVSYTKS ASEINGKLRQ NKGVINCFPS NLIKQVELLD KSFNKMKTPE 100